Nuvalent deal delivers GSK’s first-ever lung cancer approval
In a landmark moment for its oncology ambitions, GSK has secured FDA approval for Jideytro (zidesamtinib) as the…
GSK inks $10.6B Nuvalent buyout to challenge Roche and Pfizer
GSK has struck a deal to buy Nuvalent for $10.6 billion, securing two near-approval cancer therapies that could challenge…